EyePoint Pharmaceuticals (EYPT) Appoints Fred Hassan to its Board

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors.

“I am honored to welcome Fred Hassan to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. “He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future commercialization. Fred is a visionary in the industry with extensive global biopharmaceutical experience, and his analytical and strategic insights will be invaluable as we continue to make progress in bringing a potential revolutionary treatment to patients.”

“It is an honor to join the EyePoint Board of Directors at such an exciting time for the Company,” said Mr. Hassan. “I am impressed by EyePoint’s progress developing safe and effective treatments for important unmet needs in retinal disease, and I look forward to working closely with the talented management team and the Board to help bring important innovations to patients who are currently underserved by today’s treatment options.”

Fred Hassan has had an exceptionally distinguished career in the biopharmaceutical industry as the former CEO of three global pharmaceutical companies. He currently serves as Director of Warburg Pincus LLC, a global private equity firm. Previously, Mr. Hassan served as Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation from 2003 to 2009. Prior to joining Schering-Plough, he was Chairman and Chief Executive Officer of Pharmacia Corporation, a company that was formed as a result of the merger of Monsanto and Pharmacia and Upjohn, Inc. Mr. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997. Mr. Hassan previously held senior leadership positions with Wyeth, which has since been acquired by Pfizer, including Executive Vice President with responsibility for its pharmaceutical and medical products businesses. He also served as a member of the Wyeth’s board from 1995 to 1997. Earlier in his career, Mr. Hassan spent a significant tenure at Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals businesses. Mr. Hassan’s past directorships include Time Warner (2001-2018), Amgen (2015-2021) and as Chairman at Bausch & Lomb (2010-2013).

Mr. Hassan has been the recipient of numerous prominent awards, including being named CEO of the Year by The Financial Times and Scrip. He has chaired several prominent pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He received an MBA from Harvard Business School and a B.S. in chemical engineering from the Imperial College of Science and Technology at the University of London.

Additionally, the Company announced that Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from their positions as directors on the Company’s Board due to their transition to full-time roles at Merck & Co.

“On behalf of the entire Board, I would like to express my sincere gratitude to Tony and David for their outstanding service and valuable contributions to EyePoint,” said Dr. Ando. “Their strategic and scientific insights helped shape our product development pipeline and clinical strategies. EyePoint has certainly benefited from their substantial industry insight and experience.”

You May Also Be Interested In

• American Fusion receives Texas certification for its fusion engine models
• Paramount Skydance extends bond offer deadlines to August 7
• FDA issues early alert on Boston Scientific catheter tip separation risk